# US 2023/0263884 A1 · Methods and compositions for treating coronaviral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263884 A1
- Document ID: US20230263884A1
- Status: Published application
- Kind: A1
- Application number: 18/122,169
- Filed: 2023-03-16
- Published: 2023-08-24
- Earliest claimed: 2020-09-23
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Gideon SCHREIBER; Jiri ZAHRADNIK; Yinon RUDICH
- Web page: https://patentgrep.com/patent/US20230263884A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K 14/005: from viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD) is disclosed, wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501, wherein the polypeptide binds soluble, monomeric angiotensin-converting enzyme 2 (ACE2) receptor. Uses thereof are further disclosed.

## Claims

### Claim 1

A polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD), wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501, wherein the numbering of the positions of the modifications is according to UniProtKB - P0DTC2 (SEQ ID NO: 37), wherein said polypeptide binds soluble, monomeric angiotensin-converting enzyme 2 (ACE2) receptor when expressed on the surface of yeast cells with at least 50 fold higher affinity than the wild-type RBD having an amino acid sequence as set forth in SEQ ID NO: 45, when assayed under identical conditions, wherein said polypeptide comprises at least 170 amino acids of said RBD.

### Claim 2 (depends on 1)

The polypeptide of claim 1, comprising modifications at each of the positions 358, 484, 498 and 501, and optionally comprising a modification at position 460.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein said modification at position 358 comprises a I358F substitution, wherein said modification at position 484 comprises a E498K substitution, wherein said modification at position 498 comprises a Q498R substitution, or said modification at position 501 comprises a N501Y substitution.

### Claim 4 (depends on 2)

The polypeptide of claim 2, comprising the substitutions:
(i) I358F, N460K, E484K, S494P, Q498R and N501Y;
(ii) I358F, N460K, E484K, Q498R and N501Y;
(iii) I358F, E484K, Q498R and N501Y;
(iv) I358F, V445K, N460K, I468T, T470M, S477N, E484K, Q498R and N501Y; or
(v) I358F, V367W, R408D, K417V, V445K, N460K, I468T, T470M, S477N, E484K, Q498R and N501Y.

### Claim 5

An isolated polypeptide comprising an amino acid sequence at least 99 % identical to SEQ ID NO: 38, 39 or 40.

### Claim 6 (depends on 1)

The isolated polypeptide of claim 1, comprising no more than 250 amino acids of the S1 subunit of the spike protein of SARS CoV-2.

### Claim 7 (depends on 1)

An isolated polynucleotide encoding the polypeptide of claim 1.

### Claim 8

A dimer comprising two monomers linked by a linker, wherein each of said two monomers comprises an amino acid sequence encoding SARS-CoV-2 receptor-binding domain (RBD), wherein each of said monomers binds soluble, monomeric angiotensin-converting enzyme 2 receptor when expressed on the surface of yeast cells with at least 50 fold higher affinity than the wild-type RBD having an amino acid sequence as set forth in SEQ ID NO: 45, when assayed under identical conditions.

### Claim 9 (depends on 8)

The dimer of claim 8, wherein each of said monomers comprises a modification at position 358, wherein the numbering of the position of the modification is according to UniProtKB - P0DTC2 (SEQ ID NO: 37).

### Claim 10 (depends on 8)

The dimer of claim 8, wherein the amino acid sequence of said two monomers is at least 99 % identical to SEQ ID NO: 38, 39 or 40.

### Claim 11 (depends on 8)

The dimer of claim 8, wherein a first of said two monomers comprises an amino acid sequence as set forth in SEQ ID NO: 39 and a second of said two monomers comprises an amino acid sequence as set forth in SEQ ID NO: 40.

### Claim 12 (depends on 8)

An isolated polynucleotide, encoding the dimer of claim 8, wherein said linker is a peptide linker.

### Claim 13 (depends on 12)

The isolated polynucleotide of claim 12, being an mRNA.

### Claim 14 (depends on 1)

A vaccine comprising the isolated polypeptide of claim 1 or a polynucleotide encoding said polypeptide and an immunologically acceptable carrier.

### Claim 15 (depends on 14)

The vaccine of claim 14, further comprising an adjuvant.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising as an active ingredient the isolated polypeptide of claim 1 or a polynucleotide encoding said polypeptide, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, being formulated for inhalation.

### Claim 18 (depends on 1)

A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polypeptide of claim 1 or a polynucleotide encoding said polypeptide, thereby treating the coronavirus infection.

### Claim 19 (depends on 18)

The method of claim 18, wherein said administering is effected by inhalation.

### Claim 20 (depends on 1)

An article of manufacture comprising the polypeptide of claim 1, or a polynucleotide encoding said polypeptide and an anti-inflammatory agent.
